CD7 CAR-T cells (Institute of Hematology & Blood Diseases Hospital)

This is an investigational CD7-targeted chimeric antigen receptor (CAR) T-cell therapy being developed by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. The therapy utilizes T cells, which can be either autologous or donor-derived, genetically engineered to express a CAR targeting the CD7 protein. CD7 is a transmembrane glycoprotein highly expressed on the surface of T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). A significant challenge in developing CD7-targeted therapies is fratricide, where the CAR-T cells target each other due to their own CD7 expression; this is typically managed through gene-editing techniques to knock out the CD7 gene in the therapeutic cells. This specific product is being evaluated in clinical trials for newly diagnosed high-risk T-LBL/ALL patients who have achieved their first complete remission (CR1), as well as in relapsed or refractory settings.

Other names

CD7 CAR-T cellsCD-7 CAR-T cellsCD 7 CAR-T cellsCD7-targeted CAR-T cellsCD-7-targeted CAR-T cellsCD 7-targeted CAR-T cellsanti-CD7 CAR-T cellsanti-CD-7 CAR-T cellsanti-CD 7 CAR-T cells